Dapagliflozin净销售预测与市场规模分析（2034 年）

推动Dapagliflozin净成长的关键因素

1. 扩大市场占有率并增加新患者数量

• 由于Dapagliflozin具有广泛的心血管代谢作用，因此在糖尿病、心臟衰竭和慢性肾臟病(CKD) 领域继续获得市场份额。
• 新患者数量的不断增长，尤其是在传统糖尿病领域之外的患者，支撑着处方笺和销售量的稳定增长。
• 医生们的深刻理解和基于指南的采纳，巩固了其作为心臟病学、肾臟病学和内分泌学实践中基石疗法的地位。

2. 主要适应症的扩展

• 2 型糖尿病 (T2DM)：Dapagliflozin是一种成熟的 SGLT2 抑制剂，可持续提供持久的血糖控制以及体重和血压方面的益处。
• 心臟衰竭（HFrEF 和 HFpEF）：它正迅速成为糖尿病和非糖尿病患者心臟衰竭的标准治疗方法，在减少住院和心血管死亡方面取得了良好的效果。
• 慢性肾臟病（CKD）：已证实具有肾臟保护作用并能延缓疾病进展，因此在患有或未患有糖尿病的 CKD 患者中得到了更广泛的应用。
• 持续的研究和生命週期管理将探索更广泛的心血管代谢和肾臟病应用，从而加强长期市场扩张。

3. 地理扩张

• Dapagliflozin已在全球广泛应用，在北美、欧洲和主要新兴市场的应用率很高。
• 由于糖尿病盛行率上升、心臟衰竭和慢性肾臟病诊断病例增加，以及获得创新疗法的机会改善，预计亚太地区和拉丁美洲将加速成长。
• 策略定价、在地化生产和伙伴关係正在推动对成本敏感地区的市场进一步渗透。

4. 新适应症的核准

• 达格列净在糖尿病、心臟衰竭和慢性肾臟病(CKD) 领域获得多项监管核准，显着扩大了符合Dapagliflozin条件的患者群体。
• 适应症扩展到糖尿病以外，使该药物重新定位为多学科治疗方法，增强了其与其他降血糖药物的竞争力。
• 这些核准使收入来源多元化，减少了对糖尿病市场的单一依赖，并提高了长期永续性。

5. 心肾领域销售量强劲成长

• 心臟衰竭和慢性肾臟病(CKD) 领域是主要驱动因素，其持续的销售量成长势头得益于优异的临床结果和国际治疗指南的采纳。
• 真实世界和长期追踪数据进一步巩固了循环系统和肾臟科医师的信心，加速了新确诊患者和高风险患者的采用。

6. 竞争差异化与市场趋势

• 每日一次口服给药，且安全性良好，有助于提高用药的便利性和长期依从性。
• 除了血糖控制之外，Dapagliflozin还缓解疾病作用，这使它有别于传统的抗糖尿病药物。
• 与更广泛的医疗保健趋势保持一致，例如心肾代谢综合护理、早期疗育和基于价值的护理模式，是持续采用的强大驱动力。
• 真实世界数据 (RWE) 的累积正在增强多个市场支付方的接受度，并推动有利的报销决策。

Dapagliflozin的最新趋势

Dapagliflozin在心肾和代谢疾病的治疗中持续发挥核心作用。最新的临床分析和真实世界研究证实，达格列净对各种心率输出频谱的心臟衰竭患者以及非糖尿病慢性肾臟病（CKD）患者均有益处，进一步增强了医生对其的信心。持续的上市后证据和指南更新巩固了其作为基础治疗而非辅助性治疗的地位。此外，达格列净持续被纳入全球和区域临床实践指南，也支持其长期效用。同时，其生命週期管理策略着眼于在SGLT2抑制剂类药物竞争日益激烈的背景下，维持其市场成长。

《Dapagliflozin净销售预测及市场规模分析（2034）》报告核准分析了达格列净在七个主要国家（美国、四个欧盟国家（德国、法国、义大利和英国）、英国、法国和义大利）的市场情况，涵盖了已获批准的适应症（如重症血小板减少性疾病）以及潜在适应症（如新生儿修格兰氏症候群、全身性红斑性狼疮血小板系统减少症、新生儿同种干性狼疮和本报告详细描述了Dapagliflozin在上述七个主要国家（美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本）的现有使用情况、预期市场准入情况以及核准和潜在适应症的市场表现，研究週期为2020年至2034年。此外，报告还对Dapagliflozin在核准和潜在适应症中的应用进行了详细描述。这份Dapagliflozin市场报告深入分析了达格列净的研发及其他活动，包括销售预测、作用机制、剂量和给药途径以及监管里程碑。此外，报告还提供了Dapagliflozin的Dapagliflozin和当前市场表现、未来市场评估（包括对七个主要国家已通过核准和潜在适应症的Dapagliflozin市场预测分析）、SWOT分析、分析师观点、市场竞争对手的全面概述以及针对每种适应症的其他新兴治疗方法的概述。该报告还对Dapagliflozin的销售预测以及市场驱动因素进行了分析。

Dapagliflozin药物概述

Dapagliflozin（商品名： Farxiga ）是一种选择性钠-葡萄糖共同输送体2 (SGLT2) 抑制剂，主要用于治疗第2型糖尿病、心臟衰竭和慢性肾臟病。它透过抑制肾臟近端小管的SGLT2，减少葡萄糖的重吸收，从而促进糖尿、热量消耗，并以不依赖胰岛素的方式降低血糖值。它还能诱导钠排泄，从而降低血压并带来轻微的体重减轻。达格列核准每日一次口服（5-10毫克），对多种患者族群均具有心臟保护和肾臟保护作用，可减少重大心血管事件、心臟衰竭住院和肾臟疾病进展。本报告提供有关Dapagliflozin的销售、成长障碍和驱动因素、使用情况以及多种适应症的核准情况的资讯。

Dapagliflozin目前处于治疗第 2 型糖尿病患者的 III 期临床开发阶段 (NCT04634500)。

Dapagliflozin市场报告覆盖范围

本报告深入分析了以下内容：

• Dapagliflozin净的全面产品概述，包括其作用机制（MoA）、产品说明、剂量和给药方法，以及针对核准适应症（如重症肌无力）和潜在适应症（如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病症、修格兰氏症候群和全身性红斑性狼疮）的研究和开发活动。
• Dapagliflozin市场报告提供了有关监管里程碑和其他开发活动的详细资讯。
• 该报告还重点介绍了Dapagliflozin在美国、欧洲和日本已通过核准和潜在适应症的成本估算和区域差异、已报告和估计的销售额以及研发活动。
• Dapagliflozin市场报告还涵盖专利资讯、学名药药上市及其对降低成本的影响。
• 这份Dapagliflozin市场报告提供了截至 2034 年Dapagliflozin在已通过核准和潜在适应症中的当前和预测销售额。
• 此外，也全面介绍了每种适应症中新兴的后期治疗方法。
• 这份Dapagliflozin市场报告还包含 SWOT 分析，以及分析师对Dapagliflozin在已通过核准和潜在适应症方面的观点。

调查方法：

这份Dapagliflozin市场报告主要基于DelveInsight内部资料库、一手和二手研究以及产业专家团队的内部分析所获得的数据和资讯。二级资讯来源资讯和资料来自各种印刷和非印刷管道，例如搜寻引擎、新闻网站、全球监管机构网站、行业期刊、白皮书、杂誌、书籍、行业协会、行业入口网站以及对现有资料库的存取。

DelveInsight提供的Dapagliflozin分析观点

• 对Dapagliflozin市场的详细评估

这份Dapagliflozin销售市场预测报告详细评估了七大主要市场（美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本）中已通过核准的适应症（如重症肌无力）以及潜在适应症（如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮）的市场状况。报告的这一部分提供了截至2034年的Dapagliflozin净销售现况及预测数据。

• Dapagliflozin的临床评价

这份Dapagliflozin市场报告提供了已通过核准和潜在适应症的临床试验信息，包括研究干预措施、研究条件、实验状况、开始和完成日期。

Dapagliflozin的竞争格局

本报告深入分析了该领域的竞争对手和市售产品，并概述了新兴产品及其预计上市日期，这些产品将在市场上造成激烈的竞争。

Dapagliflozin市场潜力及收入预测

• Dapagliflozin净的预期市场规模及其主要适应症
• Dapagliflozin净的预期销售潜力（销售尖峰时段预测）
• Dapagliflozin净定价策略和报销情况

Dapagliflozin的竞争讯息

• 在研竞争药物数量（研发管线分析）
• Dapagliflozin与现有疗法相比的市场定位
• Dapagliflozin相对于竞争对手的优势与劣势

Dapagliflozin净监管与商业里程碑

• Dapagliflozin的关键监管核准和预计上市时间
• 商业合作、授权协议和併购活动

Dapagliflozin的临床鑑别诊断

• Dapagliflozin：与现有药物相比，具有更优的疗效和安全性
• Dapagliflozin的独特卖点

Dapagliflozin市场报告要点

• 未来几年，随着达格列净的广泛应用、处方笺的增加以及在多种免疫适应症中的更广泛应用，预计Dapagliflozin市场将发生变化，这将推动市场规模的成长。
• Dapagliflozin相关企业正在开发以治疗和改善疾病状态的新方法为重点的治疗方法，评估挑战并探索可能影响Dapagliflozin优势的机会。
• 其他用于治疗重症肌无力的新兴产品，以及诸如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮等潜在适应症，预计将对Dapagliflozin净构成激烈的市场竞争，而近期推出的后期治疗方法预计也将对市场产生重大影响。
• 它提供了Dapagliflozin在已通过核准和潜在适应症中的最新进展情况，并详细说明了监管里程碑和研发活动。
• 分析Dapagliflozin净的成本、定价趋势和市场定位，以支持免疫学领域的策略决策。
• 我们对Dapagliflozin净销售预测数据到 2034 年的详细分析将透过确定Dapagliflozin净在已通过核准和潜在适应症中的整体情况，帮助您制定治疗组合决策流程。

目录

第一章 报告概述

第二章Dapagliflozin净核准适应症概述，例如重症肌无力，以及潜在适应症，例如胎儿红血球增多症、新生儿同种免疫性血小板减少性疾病、修格兰氏症候群和全身性红斑性狼疮

• 产品详情
• Dapagliflozin的临床开发
  • Dapagliflozin的临床试验
  • Dapagliflozin临床试验信息
  • 安全性和有效性
• 其他发展活动
• 产品简介

第三章Dapagliflozin（非处方药）的竞争格局

第四章 竞争格局（后期达格Dapagliflozin疗法）

第五章Dapagliflozin市场评估

• Dapagliflozin市场展望：已通过核准和潜在适应症
• 对七个主要国家的分析
  • Dapagliflozin净在七个主要国家已已通过核准和潜在适应症的市场规模
• 各国市场
  • 美国Dapagliflozin市场规模（已通过核准适应症和潜在适应症）
  • 德国Dapagliflozin市场规模（已通过核准和潜在适应症）
  • Dapagliflozin净在英国的市场规模（已通过核准和潜在适应症）

第六章Dapagliflozin的SWOT分析

第七章 分析师观点

第八章附录

第九章 DelveInsight 服务

第十章 免责声明

第十一章 关于 DelveInsight

第十二章 报告购买选项

Key Factors Driving Dapagliflozin Growth

1. Market Share Gains and New Patient Starts

• Dapagliflozin continues to gain market share across diabetes, heart failure, and chronic kidney disease (CKD) segments, driven by its broad cardiometabolic benefits.
• Rising new patient initiations, particularly outside the traditional diabetes space, are supporting steady prescription and volume growth.
• Strong physician familiarity and guideline-driven adoption are reinforcing its position as a foundational therapy in cardiology, nephrology, and endocrinology practices.

2. Expansion Across Key Indications

• Type 2 Diabetes Mellitus (T2DM): Dapagliflozin remains a well-established SGLT2 inhibitor, offering durable glycemic control along with weight and blood pressure benefits.
• Heart Failure (HFrEF and HFpEF): Rapid uptake as a standard-of-care therapy for heart failure regardless of diabetes status, supported by strong outcomes in reducing hospitalization and cardiovascular death.
• Chronic Kidney Disease (CKD): Increasing use in CKD patients with and without diabetes, driven by demonstrated renal protection and slowed disease progression.
• Ongoing research and lifecycle management continue to explore broader cardiometabolic and renal applications, reinforcing long-term market expansion.

3. Geographic Expansion

• Dapagliflozin has achieved wide global penetration, with strong adoption across North America, Europe, and key emerging markets.
• Asia-Pacific and Latin America are expected to witness accelerated growth due to rising diabetes prevalence, increasing diagnosis of heart failure and CKD, and improved access to innovative therapies.
• Strategic pricing, local manufacturing, and partnerships are enabling deeper market reach in cost-sensitive regions.

4. New Indication Approvals

• Multiple regulatory approvals across diabetes, heart failure, and CKD have significantly expanded Dapagliflozin's addressable patient population.
• Label expansions beyond diabetes have repositioned the drug as a multispecialty therapy, strengthening its competitive profile against other glucose-lowering agents.
• These approvals diversify revenue streams and reduce dependence on the diabetes-only market, enhancing long-term sustainability.

5. Strong Cardio-Renal Volume Momentum

• Heart failure and CKD segments are major growth drivers, with sustained volume momentum driven by strong clinical outcomes and inclusion in international treatment guidelines.
• Real-world and long-term follow-up data continue to reinforce confidence among cardiologists and nephrologists, accelerating uptake in newly diagnosed and high-risk patients.

6. Competitive Differentiation and Market Trends

• Once-daily oral administration and a well-established safety profile provide convenience and support long-term adherence.
• Disease-modifying benefits beyond glucose control differentiate Dapagliflozin from traditional antidiabetic therapies.
• Alignment with broader healthcare trends, including integrated cardio-renal-metabolic care, early intervention, and value-based healthcare models, strongly supports continued adoption.
• Growing real-world evidence (RWE) is strengthening payer acceptance and supporting favorable reimbursement decisions in multiple markets.

Dapagliflozin Recent Developments

Dapagliflozin have continued to emphasize its central role in cardio-renal-metabolic disease management. Updated clinical analyses and real-world studies have reinforced its benefits in heart failure across the ejection fraction spectrum and in CKD patients without diabetes, further expanding prescriber confidence. Ongoing post-marketing evidence and guideline updates have strengthened its positioning as a foundational therapy rather than an adjunct treatment. Additionally, continued inclusion in global and regional clinical practice guidelines has underscored its long-term relevance, while lifecycle management strategies focus on sustaining growth amid increasing competition within the SGLT2 inhibitor class.

"Dapagliflozin Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Dapagliflozin for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the 7MM. A detailed picture of Dapagliflozin's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Dapagliflozin for approved and potential indications. The Dapagliflozin market report provides insights about Dapagliflozin's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Dapagliflozin performance, future market assessments inclusive of the Dapagliflozin market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Dapagliflozin sales forecasts, along with factors driving its market.

Dapagliflozin Drug Summary

Dapagliflozin, marketed as Farxiga, is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used primarily for managing type 2 diabetes mellitus, heart failure, and chronic kidney disease. By blocking SGLT2 in the proximal renal tubules, it prevents glucose reabsorption, promoting glycosuria, caloric loss, and blood glucose reduction independent of insulin, while also inducing natriuresis for blood pressure lowering and modest weight loss. Approved for oral once-daily dosing (5-10 mg), it offers cardioprotective and renoprotective benefits, reducing major adverse cardiovascular events, heart failure hospitalizations, and kidney disease progression across broad patient populations. The report provides Dapagliflozin's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Dapagliflozin is in the Phase III stage of clinical development for the treatment of patients with Type 2 Diabetes Mellitus (NCT04634500).

Scope of the Dapagliflozin Market Report

The report provides insights into:

• A comprehensive product overview including the Dapagliflozin MoA, description, dosage and administration, research and development activities in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus.
• Elaborated details on Dapagliflozin regulatory milestones and other development activities have been provided in Dapagliflozin market report.
• The report also highlights Dapagliflozin's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Dapagliflozin market report also covers the patents information, generic entry and impact on cost cut.
• The Dapagliflozin market report contains current and forecasted Dapagliflozin sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Dapagliflozin market report also features the SWOT analysis with analyst views for Dapagliflozin in approved and potential indications.

Methodology:

The Dapagliflozin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dapagliflozin Analytical Perspective by DelveInsight

• In-depth Dapagliflozin Market Assessment

This Dapagliflozin sales market forecast report provides a detailed market assessment of Dapagliflozin for approved indication like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Dapagliflozin sales data uptil 2034.

• Dapagliflozin Clinical Assessment

The Dapagliflozin market report provides the clinical trials information of Dapagliflozin for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Dapagliflozin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Dapagliflozin Market Potential & Revenue Forecast

• Projected market size for the Dapagliflozin and its key indications
• Estimated Dapagliflozin sales potential (Dapagliflozin peak sales forecasts)
• Dapagliflozin Pricing strategies and reimbursement landscape

Dapagliflozin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Dapagliflozin Market positioning compared to existing treatments
• Dapagliflozin Strengths & weaknesses relative to competitors

Dapagliflozin Regulatory & Commercial Milestones

• Dapagliflozin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Dapagliflozin Clinical Differentiation

• Dapagliflozin Efficacy & safety advantages over existing drugs
• Dapagliflozin Unique selling points

Dapagliflozin Market Report Highlights

• In the coming years, the Dapagliflozin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Dapagliflozin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Dapagliflozin's dominance.
• Other emerging products for Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus are expected to give tough market competition to Dapagliflozin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Dapagliflozin in approved and potential indications.
• Analyse Dapagliflozin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Dapagliflozin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Dapagliflozin in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Dapagliflozin? How strong is Dapagliflozin's clinical and commercial performance?
• What is Dapagliflozin's clinical trial status in each individual indications such as Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Dapagliflozin Manufacturers?
• What are the key designations that have been granted to Dapagliflozin for approved and potential indications? How are they going to impact Dapagliflozin's penetration in various geographies?
• What is the current and forecasted Dapagliflozin market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Dapagliflozin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Dapagliflozin for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Dapagliflozin? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Dapagliflozin Overview in approved indications like Myasthenia gravis; as well as potential indications like Fetal erythroblastosis; Neonatal alloimmune thrombocytopenia; Sjogren's syndrome; and Systemic lupus erythematosus

• 2.1. Product Detail
• 2.2. Dapagliflozin Clinical Development
  • 2.2.1. Dapagliflozin Clinical studies
  • 2.2.2. Dapagliflozin Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Dapagliflozin Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Dapagliflozin Therapies)

5. Dapagliflozin Market Assessment

• 5.1. Dapagliflozin Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Dapagliflozin Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Dapagliflozin Market Size in the United States for approved and potential indications
  • 5.3.2. Dapagliflozin Market Size in Germany for approved and potential indications
  • 5.3.3. Dapagliflozin Market Size in France for approved and potential indications
  • 5.3.4. Dapagliflozin Market Size in Italy for approved and potential indications
  • 5.3.5. Dapagliflozin Market Size in Spain for approved and potential indications
  • 5.3.6. Dapagliflozin Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Dapagliflozin Market Size in Japan for approved and potential indications

6. Dapagliflozin SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Dapagliflozin, Clinical Trial Description, 2023
• Table 2: Dapagliflozin, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Dapagliflozin's pricing and cost Assumptions
• Table 6: Dapagliflozin's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Dapagliflozin Market Size in the US, in USD million (2020-2034)
• Table 8: Dapagliflozin Market Size in Germany, in USD million (2020-2034)
• Table 9: Dapagliflozin Market Size in France, in USD million (2020-2034)
• Table 10: Dapagliflozin Market Size in Italy, in USD million (2020-2034)
• Table 11: Dapagliflozin Market Size in Spain, in USD million (2020-2034)
• Table 12: Dapagliflozin Market Size in the UK, in USD million (2020-2034)
• Table 13: Dapagliflozin Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Dapagliflozin's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Dapagliflozin Market Size in the United States, USD million (2020-2034)
• Figure 3: Dapagliflozin Market Size in Germany, USD million (2020-2034)
• Figure 4: Dapagliflozin Market Size in France, USD million (2020-2034)
• Figure 5: Dapagliflozin Market Size in Italy, USD million (2020-2034)
• Figure 6: Dapagliflozin Market Size in Spain, USD million (2020-2034)
• Figure 7: Dapagliflozin Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Dapagliflozin Market Size in Japan, USD million (2020-2034)